poisar

Stocks · News reference

Macquarie Analyst Comments on ResMed's Annual Guidance

Fiscal.ai

An analyst at Macquarie suggests that ResMed's reiteration of its annual revenue guidance implies a potential operational upgrade for the company.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAmerican Academy Of Sleep Medicine

    AASM releases roadmap to improve women’s sleep health

    The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.

  2. The Motley FoolThe Motley Fool Team

    ResMed: 3 Key Takeaways for Long-Term Investors

    ResMed reported 7% core revenue growth in Q1 FY2027 with expanding gross margins driven by manufacturing productivity gains. The company noted that patients on GLP-1 obesity medications are 11% more likely to adopt CPAP therapy for sleep apnea and show higher retention rates. ResMed returned over $1 billion to shareholders this quarter through dividends and share repurchases following the sale of its MatrixCare business, reflecting confidence in its 2030 strategy targeting high single-digit revenue growth with higher earnings growth.